The Royal London Hospital in Whitechapel has confirmed it will retain its Same Day Emergency Care (SDEC) unit for sickle cell patients after a public campaign and a new £1m investment, according to Barts Health NHS Trust. The unit, which operated as a pilot scheme from September 2022 to January 2023, offered an alternative to A&E admissions for individuals living with sickle cell disease, a condition that disproportionately affects people of Black and Caribbean descent.

Impact on Patient Care and Health Inequalities

The SDEC unit was launched with the aim of improving patient outcomes, reducing health inequalities, and preventing unnecessary hospital admissions. According to the trust, one in seven of all sickle cell patients in the UK live in north-east London and Essex, where its hospitals treat around 900 individuals with the condition.

Dr Raj Thuraisingham, the divisional director for medicine at the Royal London Hospital, emphasized the importance of expanding care for those living with this lifelong condition. ‘Improving services for people living with this lifelong condition is one of our priorities,’ he said. ‘We worked hard to improve our community outreach provision.’

The SDEC unit also enhanced the hospital’s capacity to perform automated red cell exchange transfusions, a procedure that significantly reduces complications and improves quality of life for sickle cell patients. This treatment, which is more efficient and less invasive than traditional methods, has been a key factor in the unit’s success.

Public Campaign and Community Response

The decision to continue the SDEC unit came after a public campaign led by the Sickle Cell Society and other advocacy groups. In a post on Instagram, the Sickle Cell Society announced: ‘Breaking News: We have been in discussions with commissioners regarding the Same Day Emergency Care Unit at The Royal London Hospital, and as a result, it will REOPEN.’

The post received widespread support, with dozens of people commenting on the news. One user wrote: ‘Absolutely brilliant news! See community when we all pull together!’ The society said it would provide more details about the reopening in the coming days.

Barts Health NHS Trust stated in a statement that sickle cell disease is ‘debilitating, dangerous, and a disease that disproportionately affects people from Black and Caribbean backgrounds.’ The trust emphasized that those living with the condition need more than the best medical treatment to manage a lifelong illness.

Funding and Future Plans

The trust had previously invested £2m in launching the SDEC unit in September 2022. The new £1m funding will extend the provision into 2027, ensuring continued support for patients. In addition, the trust is expecting a similar amount to be allocated for a broader focus on helping those with sickle cell manage emergencies caused by a painful crisis.

The SDEC unit was part of a larger effort to address the urgent needs of the sickle cell community in London. The pilot scheme, which saw over 200 patients treated during its operation, demonstrated the value of providing specialized care outside of traditional emergency departments.

Dr Thuraisingham added that the hospital is committed to improving access to care for those living with sickle cell disease. ‘We are looking at ways to expand this model to other hospitals within the trust and to support patients across the region,’ he said.

The continued operation of the SDEC unit is a significant step forward in addressing health disparities and ensuring that those living with sickle cell disease receive the timely and appropriate care they need. With ongoing funding and community support, the hospital aims to reduce the burden on A&E departments and improve outcomes for patients in the long term.